PHVS
Pharvaris N.V.
Price Chart
Latest Quote
$33.10
+0.30 (+0.91%)
Current Price
| Previous Close | $32.80 |
| Open | $33.12 |
| Day High | $33.97 |
| Day Low | $32.24 |
| Volume | 174,791 |
Stock Information
Note: Financial values converted from EUR to USD
| Shares Outstanding | 69.88M |
| Total Debt | $845K |
| Cash Equivalents | $282.33M |
| Net Income | $-192.71M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.31B |
| EPS (TTM) | $-3.16 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.90B |
| Income | $-192.71M |
| Book/sh | $4.20 |
| Cash/sh | $3.53 |
| Employees | 134 |
Financial Ratios
| Quick Ratio | 10.99 |
| Current Ratio | 11.24 |
| Debt/Eq | 0.31 |
Returns & Margins
| ROA | -42.31% |
| ROE | -73.02% |
Ownership
| Insider Ownership | 6.14% |
| Institutional Ownership | 85.23% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -12.45 |
| P/B | 7.88 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $45.81 |
Technical Indicators
| SMA20 | $31.00 |
| SMA50 | $30.08 |
| SMA200 | $26.49 |
| RSI | 70.33 |
| ATR | 1.6457 |
| Shares Float | 40.17M |
| Short Float | 1.23% |
| Short Ratio | 1.67 |
| Volatility | -2.33 |
| Rel Volume | 0.55 |
Performance History
| Week | +7.75% |
| Month | +12.39% |
| Quarter | +27.31% |
| 6 Months | +37.40% |
| YTD | +25.00% |
| Year | +98.92% |
| 3 Years | +195.54% |
| 5 Years | +58.91% |
| 10 Years | +14.14% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $33.10 | 174,791 |
| 2026-06-18 | $32.80 | 182,200 |
| 2026-06-17 | $33.41 | 287,400 |
| 2026-06-16 | $31.46 | 149,300 |
| 2026-06-15 | $31.54 | 123,000 |
| 2026-06-12 | $30.72 | 180,200 |
| 2026-06-11 | $32.20 | 396,700 |
| 2026-06-10 | $31.51 | 183,700 |
| 2026-06-09 | $31.60 | 465,900 |
| 2026-06-08 | $31.59 | 552,700 |
| 2026-06-05 | $31.09 | 775,100 |
| 2026-06-04 | $31.63 | 361,800 |
| 2026-06-03 | $30.14 | 704,000 |
| 2026-06-02 | $28.98 | 349,700 |
| 2026-06-01 | $29.10 | 143,400 |
| 2026-05-29 | $30.16 | 413,900 |
| 2026-05-28 | $29.86 | 255,000 |
| 2026-05-27 | $29.47 | 141,800 |
| 2026-05-26 | $29.88 | 191,700 |
| 2026-05-22 | $29.68 | 291,100 |
About Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
đ° Latest News
What This Fundâs $14 Million Ocular Therapeutix Exit Could Signal for Investors
Motley Fool âĸ 2026-05-19T17:26:23Z
Pharvaris Equity Raise Supports Late Stage HAE Push And Valuation Case
Simply Wall St. âĸ 2026-05-14T06:13:17Z
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000
Motley Fool âĸ 2026-05-11T20:49:29Z
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next
Motley Fool âĸ 2026-04-30T00:42:01Z
KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped Too
Investor's Business Daily âĸ 2026-04-29T20:03:45Z
Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors.
Motley Fool âĸ 2026-04-13T14:44:04Z
Did Phase 3 Completion and 2025 Losses Just Shift Pharvarisâ (PHVS) Investment Narrative?
Simply Wall St. âĸ 2026-04-07T00:19:36Z
Pharvaris' Deucrictibant Could Be a Game Changer Pending Phase III Results, RBC Says
MT Newswires âĸ 2026-04-06T15:14:41ZDoes Pharvaris (PHVS) Have the Potential to Rally 59.93% as Wall Street Analysts Expect?
Zacks âĸ 2026-04-01T13:55:02Z
BioCryst Shares Remain Undervalued, RBC Says
MT Newswires âĸ 2026-03-25T15:18:47Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $194,773,385 | $167,092,731 | $111,152,208 | $99,454,753 |
| Other Income Expense | $-11,756,793 | $9,025,247 | $-3,574,563 | $12,731,266 |
| Net Non Operating Interest Income Expense | $7,296,920 | $6,219,233 | $233,994 | $-45,021 |
| Total Other Finance Cost | $-7,296,920 | $-6,219,233 | $-233,994 | $45,021 |
| Operating Expense | $194,773,385 | $167,092,731 | $111,152,208 | $99,454,753 |
| General And Administrative Expense | $52,006,644 | $54,048,209 | $35,942,868 | $33,649,537 |
| Interest Expense | - | - | - | $18,471 |
| Interest Expense Non Operating | - | - | - | $18,471 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-201,513,223 | $-153,941,407 | $-115,695,673 | $-87,547,367 |
| Net Interest Income | $7,296,920 | $6,219,233 | $233,994 | $-45,021 |
| Normalized Income | $-192,789,682 | $-160,638,141 | $-113,043,347 | $-96,993,966 |
| Net Income From Continuing And Discontinued Operation | $-201,513,223 | $-153,941,407 | $-115,695,673 | $-87,547,367 |
| Net Income Common Stockholders | $-201,513,223 | $-153,941,407 | $-115,695,673 | $-87,547,367 |
| Net Income | $-201,513,223 | $-153,941,407 | $-115,695,673 | $-87,547,367 |
| Net Income Including Noncontrolling Interests | $-201,513,223 | $-153,941,407 | $-115,695,673 | $-87,547,367 |
| Net Income Continuous Operations | $-201,513,223 | $-153,941,407 | $-115,695,673 | $-87,547,367 |
| Pretax Income | $-199,233,258 | $-151,848,250 | $-114,492,777 | $-86,768,508 |
| Operating Income | $-194,773,385 | $-167,092,731 | $-111,152,208 | $-99,454,753 |
| Per Share | ||||
| Diluted EPS | $-3.41 | $-2.84 | $-3.02 | $-2.60 |
| Basic EPS | $-3.41 | $-2.84 | $-3.02 | $-2.60 |
| Other | ||||
| Tax Effect Of Unusual Items | $-3,033,253 | $2,328,514 | $-922,237 | $3,284,667 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-182,536,774 | $-175,808,812 | $-107,282,254 | $-112,010,608 |
| Total Unusual Items | $-11,756,793 | $9,025,247 | $-3,574,563 | $12,731,266 |
| Total Unusual Items Excluding Goodwill | $-11,756,793 | $9,025,247 | $-3,574,563 | $12,731,266 |
| Reconciled Depreciation | $479,818 | $309,166 | $295,390 | $175,411 |
| EBITDA (Bullshit earnings) | $-194,293,568 | $-166,783,565 | $-110,856,817 | $-99,279,342 |
| EBIT | $-194,773,385 | $-167,092,731 | $-111,152,208 | $-99,454,753 |
| Diluted Average Shares | $67,850,947 | $61,957,270 | $44,032,171 | $38,520,441 |
| Basic Average Shares | $67,850,947 | $61,957,270 | $44,032,171 | $38,520,441 |
| Diluted NI Availto Com Stockholders | $-201,513,223 | $-153,941,407 | $-115,695,673 | $-87,547,367 |
| Tax Provision | $2,279,964 | $2,093,157 | $1,202,896 | $778,859 |
| Gain On Sale Of Security | $-11,756,793 | $9,025,247 | $-3,574,563 | $12,731,266 |
| Research And Development | $142,766,741 | $113,044,522 | $75,209,340 | $65,805,216 |
| Selling General And Administration | $52,006,644 | $54,048,209 | $35,942,868 | $33,649,537 |
| Other Gand A | $25,467,111 | $32,390,099 | $20,672,358 | $18,183,320 |
| Salaries And Wages | $26,539,534 | $21,658,110 | $15,270,510 | $15,466,217 |
| Insurance And Claims | - | - | $6,917,665 | $7,390,421 |
Fetched: 2026-06-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $311,130,068 | $307,100,256 | $440,472,948 | $171,188,226 |
| Total Assets | $345,744,888 | $334,183,662 | $457,270,815 | $192,376,380 |
| Total Non Current Assets | $2,622,747 | $2,242,446 | $966,969 | $1,016,449 |
| Non Current Deferred Assets | $1,017,722 | $544,038 | $444,465 | $297,973 |
| Non Current Deferred Taxes Assets | $1,017,722 | $544,038 | $444,465 | $297,973 |
| Current Assets | $343,122,141 | $331,941,216 | $456,303,847 | $191,359,931 |
| Prepaid Assets | $3,369,899 | $6,591,380 | $5,688,598 | $4,638,439 |
| Receivables | $5,219,776 | $3,377,123 | $1,191,678 | $438,660 |
| Taxes Receivable | $5,219,776 | $3,377,123 | $1,191,678 | $438,660 |
| Cash Cash Equivalents And Short Term Investments | $334,532,467 | $321,972,712 | $448,711,546 | $185,614,649 |
| Cash And Cash Equivalents | $334,532,467 | $321,972,712 | $448,711,546 | $185,614,649 |
| Other Current Assets | - | - | $712,025 | $668,183 |
| Accounts Receivable | - | - | - | $0 |
| Debt | ||||
| Total Debt | $890,925 | $988,038 | $274,005 | $501,000 |
| Long Term Debt And Capital Lease Obligation | $661,297 | $732,931 | $49,964 | $286,063 |
| Current Debt And Capital Lease Obligation | $229,628 | $255,106 | $224,041 | $214,937 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $34,614,820 | $27,083,406 | $16,797,867 | $21,188,154 |
| Total Non Current Liabilities Net Minority Interest | $661,297 | $732,931 | $49,964 | $286,063 |
| Current Liabilities | $33,953,523 | $26,350,474 | $16,747,903 | $20,902,091 |
| Payables And Accrued Expenses | $20,611,791 | $17,117,973 | $9,766,107 | $17,279,575 |
| Payables | $6,945,056 | $5,922,866 | $3,830,309 | $8,196,331 |
| Total Tax Payable | $1,079,492 | $689,582 | $493,086 | $1,338,702 |
| Accounts Payable | $5,865,564 | $5,233,283 | $3,337,223 | $6,857,630 |
| Other Non Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $311,130,068 | $307,100,256 | $440,472,948 | $171,188,226 |
| Total Equity Gross Minority Interest | $311,130,068 | $307,100,256 | $440,472,948 | $171,188,226 |
| Stockholders Equity | $311,130,068 | $307,100,256 | $440,472,948 | $171,188,226 |
| Gains Losses Not Affecting Retained Earnings | $57,914,857 | $45,703,435 | $31,976,384 | $23,182,414 |
| Other Equity Adjustments | $58,224,719 | $45,545,474 | $31,993,111 | $23,132,764 |
| Retained Earnings | $-664,750,828 | $-461,354,474 | $-304,987,499 | $-188,311,590 |
| Other | ||||
| Ordinary Shares Number | $74,791,356 | $62,368,948 | $59,972,711 | $38,784,787 |
| Share Issued | $74,791,356 | $62,368,948 | $59,972,711 | $38,784,787 |
| Tangible Book Value | $311,130,068 | $307,100,256 | $440,472,948 | $171,188,226 |
| Invested Capital | $311,130,068 | $307,100,256 | $440,472,948 | $171,188,226 |
| Working Capital | $309,168,618 | $305,590,741 | $439,555,944 | $170,457,840 |
| Capital Lease Obligations | $890,925 | $988,038 | $274,005 | $501,000 |
| Total Capitalization | $311,130,068 | $307,100,256 | $440,472,948 | $171,188,226 |
| Foreign Currency Translation Adjustments | $-309,862 | $157,961 | $-16,727 | $49,650 |
| Additional Paid In Capital | $908,991,076 | $715,267,021 | $706,287,329 | $331,663,226 |
| Capital Stock | $8,974,963 | $7,484,274 | $7,196,734 | $4,654,175 |
| Common Stock | $8,974,963 | $7,484,274 | $7,196,734 | $4,654,175 |
| Long Term Capital Lease Obligation | $661,297 | $732,931 | $49,964 | $286,063 |
| Current Capital Lease Obligation | $229,628 | $255,106 | $224,041 | $214,937 |
| Pensionand Other Post Retirement Benefit Plans Current | $13,112,104 | $8,977,396 | $6,757,755 | $3,407,578 |
| Current Accrued Expenses | $13,666,734 | $11,195,107 | $5,935,798 | $9,083,244 |
| Net PPE | $1,605,024 | $1,698,408 | $522,504 | $718,476 |
| Accumulated Depreciation | $-469,418 | $-252,478 | $-143,793 | $-75,153 |
| Gross PPE | $2,074,443 | $1,950,886 | $666,297 | $793,629 |
| Other Properties | $2,074,443 | $1,950,886 | $666,297 | $793,629 |
Fetched: 2026-06-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-157,401,352 | $-138,396,909 | $-106,823,107 | $-77,172,753 |
| Operating Activities | ||||
| Operating Cash Flow | $-157,212,547 | $-137,779,767 | $-106,719,903 | $-77,030,195 |
| Cash Flow From Continuing Operating Activities | $-157,212,547 | $-137,779,767 | $-106,719,903 | $-77,030,195 |
| Operating Gains Losses | $13,467,606 | $-8,405,823 | $3,204,995 | $-12,731,266 |
| Investing Activities | ||||
| Capital Expenditure | $-188,805 | $-617,142 | $-103,204 | $-142,558 |
| Investing Cash Flow | $-188,805 | $-617,142 | $-103,204 | $-142,558 |
| Cash Flow From Continuing Investing Activities | $-188,805 | $-617,142 | $-103,204 | $-142,558 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $196,969,411 | $2,573,933 | $393,291,985 | $11,021,750 |
| Financing Cash Flow | $184,203,696 | $3,069,796 | $373,199,870 | $9,921,284 |
| Cash Flow From Continuing Financing Activities | $184,203,696 | $3,069,796 | $373,199,870 | $9,921,284 |
| Net Other Financing Charges | $-12,514,524 | $678,977 | $-19,839,211 | $-963,379 |
| Net Common Stock Issuance | $196,969,411 | $2,573,933 | $393,291,985 | $11,021,750 |
| Common Stock Issuance | $196,969,411 | $2,573,933 | $393,291,985 | $11,021,750 |
| Other | ||||
| Repayment Of Debt | $-251,190 | $-183,114 | $-252,904 | $-137,088 |
| End Cash Position | $334,532,467 | $321,972,712 | $448,711,546 | $185,614,649 |
| Beginning Cash Position | $321,972,712 | $448,711,546 | $185,614,649 | $240,111,378 |
| Effect Of Exchange Rate Changes | $-14,242,589 | $8,588,280 | $-3,279,865 | $12,754,740 |
| Changes In Cash | $26,802,344 | $-135,327,113 | $266,376,762 | $-67,251,469 |
| Net Issuance Payments Of Debt | $-251,190 | $-183,114 | $-252,904 | $-137,088 |
| Net Long Term Debt Issuance | $-251,190 | $-183,114 | $-252,904 | $-137,088 |
| Long Term Debt Payments | $-251,190 | $-183,114 | $-252,904 | $-137,088 |
| Net PPE Purchase And Sale | $-188,805 | $-617,142 | $-103,204 | $-142,558 |
| Purchase Of PPE | $-188,805 | $-617,142 | $-103,204 | $-142,558 |
| Taxes Refund Paid | $-2,487,366 | $-3,173,812 | $-1,271,258 | $-209,685 |
| Interest Received Cfo | $471,103 | $6,212,976 | $271,868 | - |
| Change In Working Capital | $8,744,441 | $6,755,313 | $-6,723,999 | $9,607,637 |
| Change In Other Current Assets | $2,001,892 | $-156,387 | $-1,094,003 | $-2,880,004 |
| Change In Payables And Accrued Expense | $7,122,568 | $6,951,058 | $-5,582,914 | $12,123,366 |
| Change In Accrued Expense | $7,152,284 | $5,054,998 | $-797,973 | $7,644,085 |
| Change In Payable | $-29,716 | $1,896,060 | $-4,784,940 | $4,479,282 |
| Change In Receivables | $-380,019 | $-39,358 | $-47,082 | $364,276 |
| Other Non Cash Items | $-504,176 | $-6,219,233 | $-233,994 | $45,021 |
| Stock Based Compensation | $21,849,286 | $18,589,897 | $12,229,871 | $13,016,629 |
| Depreciation Amortization Depletion | $479,818 | $309,166 | $295,390 | $175,411 |
| Depreciation And Amortization | $479,818 | $309,166 | $295,390 | $175,411 |
| Depreciation | $479,818 | $309,166 | $295,390 | $175,411 |
| Net Foreign Currency Exchange Gain Loss | $13,467,606 | $-8,405,823 | $3,204,995 | $-12,731,266 |
| Net Income From Continuing Operations | $-199,233,258 | $-151,848,250 | $-114,492,777 | $-86,768,508 |
| Interest Paid Cfo | - | - | - | $-165,435 |
Fetched: 2026-06-21